Evaluation of commercial Guardant360 ctDNA test in metastatic prostate cancer
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.omicsdi.org/dataset/ega/EGAS00001003352
下载链接
链接失效反馈官方服务：
资源简介：
Circulating tumor DNA (ctDNA) sequencing provides a minimally-invasive method for tumor molecular stratification. We compared the commercial Guardant360 ctDNA test to an academic sequencing approach for profiling of metastatic prostate cancer. Plasma cell-free DNA (cfDNA) from 24 patients was sequenced with a validated, prostate cancer specific targeted research panel, and sent for simultaneous Guardant360 analysis.EGA study EGAS00001003352
创建时间：
2019-02-28
